Recent Advances with Chemotherapy for NSCLG: The ECOG Experience

David H. Johnson, Alex Y. Chang, David S. Ettinger, Kyung Mann Kim, Philip Bonomi

Research output: Contribution to journalArticle


Management of disseminated non-small-cell lung cancer has changed over the past 10 years. Newer agents, such as vinorelbine (Navelbine) and paclitaxel (Taxol), have been shown to modestly improve survival in patients with advanced disease when administered in conjunction with cisplatin (Platinol). Compared with older regimens consisting of cisplatin and a Vinca alkaloid or a podophyllotoxin, the newer regimens yield a 10-to 15-week improvement in median survival and an additional 10% to 15% in 1-year survival. Based on these results derived from randomized trials, it appears that metastatic non-small-cell lung cancer patients with good performance status should be treated with regimens containing either vinorelbine or paclitaxel in conjunction with cisplatin.

Original languageEnglish (US)
Pages (from-to)67-70
Number of pages4
Issue number1 SUPPL. 2
StatePublished - Dec 1 1998


ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Johnson, D. H., Chang, A. Y., Ettinger, D. S., Kim, K. M., & Bonomi, P. (1998). Recent Advances with Chemotherapy for NSCLG: The ECOG Experience. ONCOLOGY, 12(1 SUPPL. 2), 67-70.